Please assess the completion status of the following clinical trial:

Trial Title: V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infant per investigator, 6 through 12 weeks of age~Exclusion Criteria:~* History of congenital abdominal disorders, intussusception, or abdominal surgery~* Known or suspected impairment of immunological function~* Known hypersensitivity to any component of the rotavirus vaccine~* Prior administration of any rotavirus vaccine~* Known hypersensitivity or contraindication to any component of INFANRIX(tm) hexa~* Any infant born from a known HBsAg-positive mother~* Prior administration of any oral polio vaccine~* Receipt of one or more doses of inactivated poliovirus vaccine, diptheria, tetanus and acellular pertussis vaccine, diptheria, tetanus and pertussis vaccine, Haemophilus influenzae type b vaccine, or any hepatitis B vaccine prior to the first vaccination, or receipt of any vaccines with these antigens at any time during the course of the study~* Fever, with a rectal temperature greater than or equal to 38.1 degree C (greater than or equal to 100.5 degree F) at the time of immunization~* History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive~* Clinical evidence of active gastrointestinal illness~* Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination~* Infants residing in a household with an immunocompromised person~* Prior receipt of a blood transfusion or blood products~* Participation in another clinical study within 42 days before the beginning or anytime during the duration of the current clinical study~* Any infant who cannot be adequately followed for safety by a contact visit~* History of seizure disorders or prior history followed for safety by a contact visit~* Any condition that, in the opinion of the investigator, may interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq/Infanrix Hexa
- 2 (Type: PLACEBO_COMPARATOR): Placebo/Infanrix Hexa

Based on this trial design, predict the completion outcome and termination type (if applicable).